Latest Breaking News On - Late breaking - Page 2 : comparemela.com

Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

United statesAlexa kimballHarvard medical schoolAmerican academy of dermatologyAnnual meetingHidradenitis suppurativa clinical responseMassachusetts general hospitalNumeric rating scaleGlobal assessmentHidradenitis suppurativaAnti tnfPhase 2Late breaking

AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Alzecure pharmaStefan klotterGunnar nordvallJohan sandinVeronica lidellDr alzecure pharmaPontus forsellAzita rastiRelated neurological disordersNasdaq first north premier growth marketNerve growth factorBrain derived neurotrophic factorLate breakingDie performance strategieAssets sie

Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

United statesSan diegoFareeda hoseinBristol myers squibbAmerican college of rheumatologyAmerican collegeBristol myersSeverity index activityLate breakingCutaneous lupus

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD s The Liver Meeting® 2023 -November 10, 2023 at 08:58 am EST

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due.

United statesKitty yaleStephena harrisonSarah oconnellAustin murtaghExchange commissionAkero therapeutics incPinnacle clinical researchAmerican associationLiver diseaseLiver meetingPresentation titleDecompensated cirrhosisMedical directorBreaker abstract numberLate breaking abstract

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs

Temple universityUnited statesCorey davisVeronica eamesMark sulkowskiExchange commission onTemple university school of medicineAmerican association of liver disease onMedicine at duke university school ofExchange commissionJohns hopkins university school of medicineLifesci communicationsViral hepatitis centerDepartment of medicineInfectious diseases society of americaClinical trials group